Figure 2 | Scientific Reports

Figure 2

From: Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells

Figure 2

Ru-PIP and Olaparib combination inhibits clonogenic survival and migration ability of lung cancer cells. (a) Clonogenic survival assay of A549 lung cancer cells exposed to Ru-PIP (25 µM), Olaparib (5 µM), or both at 24 h treatment. (b) Clonogenic survival assay of A549 lung cancer cells, treated as in part a, at 48 h. Mean ± SD of two independent experiments. **P < 0.01, ***P < 0.001 by ANOVA. (c) Clonogenic survival assay of A549 cells treated with a concentration gradient of Olaparib with or without Ru-PIP (25 µM), 48 h treatment. (d) The survival fractions of A549 cells following treatments were quantified from part c. (e) Clonogenic survival assay of A549 cells treated with a concentration gradient of Ru-PIP with or without Olaparib (5 µM), 48 h treatment. (f) The survival fractions of A549 cells following treatments were quantified from part e. Mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by student’s t-test. (g) Representative images of wound healing assay for A549 cells treated with Ru-PIP (25 µM), Olaparib (5 µM), or both. Cell migration was monitored by optical microcopy at the indicated time points. Scale bar, 50 µm. (h) Quantification of percentage of wound closure for cells treated as in part e, as determined by analysis using ImageJ software. Mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by ANOVA.

Back to article page